[18F]FLT-PET in oncology: current status and opportunities. - Wikidata - wikimedia - TriplyDB

[18F]FLT-PET in oncology: current status and opportunities.

[18F]FLT-PET in oncology: current status and opportunities.

http://www.wikidata.org/entity/Q35964138

about

Monitoring of anti-cancer treatment with (18)F-FDG and (18)F-FLT PET: a comprehensive review of pre-clinical studies Imaging radiation response in tumor and normal tissue.6-[18F]fluoro-L-DOPA: a well-established neurotracer with expanding application spectrum and strongly improved radiosyntheses PET probes beyond (18)F-FDG PET Metabolic Biomarkers for Cancer Molecular imaging: 18F-FDG PET and a whole lot more.Parametric imaging of ¹⁸F-fluoro-3-deoxy-3-L-fluorothymidine PET data to investigate tumour heterogeneity.Tumor growth prediction with reaction-diffusion and hyperelastic biomechanical model by physiological data fusion.(18)F-FLT PET/CT imaging in a Wister rabbit inflammation model.FLT-PET for early response evaluation of colorectal cancer patients with liver metastases: a prospective study Dynamic small-animal PET imaging of tumor proliferation with 3'-deoxy-3'-18F-fluorothymidine in a genetically engineered mouse model of high-grade gliomas.Proof-of-concept study of monitoring cancer drug therapy with cerenkov luminescence imaging Specific biomarkers of receptors, pathways of inhibition and targeted therapies: clinical applications.A novel in vitro assay to assess phosphorylation of 3'-[(18)F]fluoro-3'-deoxythymidine.Monitoring early responses to irradiation with dual-tracer micro-PET in dual-tumor bearing mice.Molecular imaging in cancer treatment.Diagnosis and evaluation of gastric cancer by positron emission tomography Imaging of treatment response to the combination of carboplatin and paclitaxel in human ovarian cancer xenograft tumors in mice using FDG and FLT PET Highlighting the Versatility of the Tracerlab Synthesis Modules. Part 1: Fully Automated Production of [F]Labelled Radiopharmaceuticals using a Tracerlab FX(FN).Comparison of 4'-[methyl-(11)C]thiothymidine ((11)C-4DST) and 3'-deoxy-3'-[(18)F]fluorothymidine ((18)F-FLT) PET/CT in human brain glioma imaging [18F]fluorothymidine PET imaging in the diagnosis of leptomeningeal involvement with diffuse large B-cell lymphoma.Measuring proliferation in breast cancer: practicalities and applications.Usefulness of FDG, MET and FLT-PET studies for the management of human gliomas.Evaluation of arginine deiminase treatment in melanoma xenografts using (18)F-FLT PET.The effects of 5-fluoruracil treatment on 3'-fluoro-3'-deoxythymidine (FLT) transport and metabolism in proliferating and non-proliferating cultures of human tumor cells.Use of Molecular Imaging Markers of Glycolysis, Hypoxia and Proliferation ((18)F-FDG, (64)Cu-ATSM and (18)F-FLT) in a Dog with Fibrosarcoma: The Importance of Individualized Treatment Planning and Monitoring.Advances in positron emission tomographic imaging of lung cancer Molecular imaging: what can be used today.Generalized whole-body Patlak parametric imaging for enhanced quantification in clinical PET Fluorine-18-Labeled Thymidine Positron Emission Tomography (FLT-PET) as an Index of Cell Proliferation after Pharmacological Ascorbate-Based Therapy [18F]FLT-PET to predict pharmacodynamic and clinical response to cetuximab therapy in Ménétrier's disease.Utility of 3'-[(18)F]fluoro-3'-deoxythymidine as a PET tracer to monitor response to gene therapy in a xenograft model of head and neck carcinoma.Calibration test of PET scanners in a multi-centre clinical trial on breast cancer therapy monitoring using 18F-FLT.Design of radiolabelled ligands for the imaging and treatment of cancer.PET and PET/CT for response evaluation in lymphoma: current practice and developments.Promises and challenges of positron emission tomography for assessment of sarcoma in daily clinical practice.The evolving role of nuclear molecular imaging in cancer.Diagnostic Value of 11C-Methionine (MET) and 18F-Fluorothymidine (FLT) Positron Emission Tomography in Recurrent High-Grade Gliomas; Differentiation from Treatment-Induced Tissue Necrosis In vivo imaging of cellular proliferation in renal cell carcinoma using 18F-fluorothymidine PET FLT-PET imaging of radiation responses in murine tumors

P2860

Q26778463-E14B603A-F718-4A75-B28F-9DF04815B3D9 Q26798266-2827C24F-590A-4C36-BF45-52513D933055 Q26991479-94B8CDC4-2D33-4683-B293-682F28270366 Q27004457-8B79AD8A-2A6B-4B40-B3C0-94B5AB4C4657 Q28074449-0C208D2B-D107-4B7D-B949-D410E9DF46CC Q30482989-C374A53A-4B8C-43D7-8A6D-EBCCDD10D06C Q30794621-82DDC7D2-7244-4443-BCA7-ECC46CB7C016 Q30949446-8D190C62-5C3D-49F7-BBFB-3E434B362BE6 Q33769525-B03019F4-6180-43AE-B03A-EA5A9FE5446C Q33889809-B4E76669-BA9F-4C96-B7DE-2DC2BDB6ACD4 Q33924541-6B4D08B4-C667-4D24-8CCC-3AE6FF8E028C Q34083326-6DACA142-3630-41CA-9DF6-46DFA3CEBAF0 Q34203953-886EBEF0-9560-4162-9ABF-4D525B85131B Q34267713-974ACB40-6B64-4188-9674-423CCF4B00C8 Q34333124-C012DBD7-9211-44D1-9A40-75B4C3CD4C24 Q34496670-E8BCFBAD-7863-4517-B8A2-E630B6217F49 Q34661633-3125A021-1029-4245-9542-38E501AB1DA9 Q35081130-444FBC87-3149-4731-B144-6A7516C1E776 Q35108246-16E37697-6E98-4E4A-A6DA-D2D1F40FAD30 Q35266071-6D75BB43-8BC4-4F6D-A9DE-051AF28CA79E Q35496023-E35DE553-0A2B-471C-9DDE-DE46A14526AC Q35633693-069313B4-70B6-4271-8B96-B4AE7BC2C4A1 Q35912078-1EDE5285-DE55-49B8-82B6-987DE4AE1AE4 Q35957293-57A03D3B-885B-4B3F-9314-87E039077610 Q36213599-C18ABD9A-8CE6-4182-908C-9ADC3947B2E4 Q36335296-A84B3748-6774-438B-9158-D64B9F787B1D Q36341240-5C4474D7-B586-47D1-BE10-7FB5B1972A62 Q36345342-6FCEEB26-A034-4F4E-AD97-5D63A65A6906 Q36454757-DD8CB551-5534-4D5B-B841-C3169B5F76B2 Q36483845-8D0268C5-0770-4412-8B14-67A653A909F8 Q36528174-02AAECCD-EF36-491B-BB9F-6D5D8BED74A8 Q36533822-47AC265E-EA40-4D39-9CEF-078B4FDBD8DE Q36680859-02E022C2-14E7-4923-9C09-B78212A10FED Q36704588-79EC01AC-7334-48DF-A47B-686674836C7F Q36746441-1FB30A06-06B4-46D9-84EF-E5D444B53401 Q36971711-E78A24CA-B58C-4931-8C8A-82D89806F8C3 Q37011086-62FAF492-FCA2-44F3-B957-78A8C6B90B36 Q37016981-E1EF7176-2814-442A-B0B1-F6770385DB52 Q37077354-B67C245B-457D-4885-88EB-DF651628783D Q37227814-57D8CFE6-6C0C-4B59-A2AE-DC59B772B983

P2860

[18F]FLT-PET in oncology: current status and opportunities.

http://www.wikidata.org/entity/Q35964138

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh

2004年學術文章

@zh-hant

name

[18F]FLT-PET in oncology: current status and opportunities.

@ast

[18F]FLT-PET in oncology: current status and opportunities.

@en

type

label

[18F]FLT-PET in oncology: current status and opportunities.

@ast

[18F]FLT-PET in oncology: current status and opportunities.

@en

prefLabel

[18F]FLT-PET in oncology: current status and opportunities.

@ast

[18F]FLT-PET in oncology: current status and opportunities.

@en

P1433

Q35964138-859C93E5-18F3-4015-A28B-F0037E0F804E

P1476

Q35964138-54A34FBB-F53A-4A92-9A07-CEE8305540FC

P2093

Q35964138-0A24F419-B00F-472B-BDFB-2795EFD4835A

Q35964138-2CBC4364-984E-4E0D-974C-8A5E316F7510

Q35964138-897A3A63-D186-4AE5-AA6F-B834418387DA

Q35964138-98343606-20BF-4F4A-853C-CC7CA8DB6827

Q35964138-CBE1FAEF-6851-40DE-87D4-166AB60B6F57

Q35964138-D5E365FE-AA0E-4A11-85AC-F6033ADAB47F

P2888

Q35964138-29C6AB37-3134-49CA-B2F2-E266D25B936C

P304

Q35964138-079E6E30-9D60-4381-B1B3-631092E21541

P31

Q35964138-649A3258-11F8-4569-AC13-831737D93696

P356

Q35964138-5373EEC4-3D2F-4616-BBAC-BE66FA83733F

P433

Q35964138-018BA245-A60F-49EA-8E4E-A4FC6BB2CD78

P478

Q35964138-AFB0B481-8E24-4BC9-BF8F-DF98B0D8454E

P577

Q35964138-43D5D3A6-DC9A-4401-B985-7F76DA8EE898

P698

Q35964138-E5D20B4C-A384-434B-88D8-C1C19820F5D0

P356

S00259-004-1687-6

P1433

European Journal of Nuclear Medicine and Molecular Imaging

P1476

[18F]FLT-PET in oncology: current status and opportunities.

@en

P2093

Albert J H Suurmeijer

http://www.w3.org/2001/XMLSchema#string

David C P Cobben

http://www.w3.org/2001/XMLSchema#string

Harald J Hoekstra

http://www.w3.org/2001/XMLSchema#string

Lukas B Been

http://www.w3.org/2001/XMLSchema#string

Philip H Elsinga

http://www.w3.org/2001/XMLSchema#string

Pieter L Jager

http://www.w3.org/2001/XMLSchema#string

P2888

s00259-004-1687-6

P304

1659-1672

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00259-004-1687-6

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P577

2004-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15565331

http://www.w3.org/2001/XMLSchema#string